Theravance Biopharma (TBPH) Tops Q3 EPS by 7c

Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($0.48), $0.07 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $14.69 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Beike (BEKE) PT Raised to $23 at Morgan Stanley
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group